Syntax Bio

Dear Syntax Community and Friends,? ? We are excited to share John Craighead, Ph.D., joined Syntax as CEO. John brings extensive experience in cell therapy, finance and corporate development, making him an ideal leader for our next stage of growth. A few highlights of John’s career include: - Deep Cell Therapy Expertise: Over four years at Atara Biotherapeutics, with a strong academic research background in transcription regulation - Strategic Experience: Leadership roles at GRAIL, Sanofi, Lehman Brothers and Human Genome Sciences - Academic Credentials: National Science Foundation Fellowship recipient; PhD in Cell Biology from Scripps Research, La Jolla, CA Please join us in welcoming John to the team! He will play a pivotal role in advancing Syntax's vision to address the longstanding challenges in stem cell-derived therapies by directly controlling and accelerating cell differentiation.

Thrilled to see Syntax listed as one of the top 12 startups to watch in Chicago in 2025. Brad Merrill Ryan Clarke Nikolas Balanis, PhD Nick Timmins Matthew MacDougall Renee de Pooter Caspian Harding Stephen Arnovitz Michaele McGregor https://lnkd.in/gnYdaXr4

Syntax Bio is #hiring! We are looking for an Associate Director/Director to join us and help lead our iPSC & Synthetic Biology research. Check out the post below and please reach out to [email protected] link to role https://lnkd.in/gmFWkvHt

Generation 3.0 proGuides are now here. This is the story behind how our core technology was engineered to be much more efficient and capable of >5 sequential steps. This ultimately enables a cell to be programmed via sequential CRISPR activation of endogenous genes, all through a single delivery of plasmid DNAs. https://lnkd.in/gwcw9FaV

We’re excited to announce that Syntax Bio is officially out of stealth! For the past three years, Founding CEO Ryan Clarke and his cofounders Professor Brad Merrill and Nikolas Balanis, PhD have been working on the Cellgorithm platform to revolutionize the production of cell therapies. Clarke and current Syntax CEO John Flavin recently sat down with Crain's Chicago Business journalist, Katherine Davis to discuss the company’s recent raise and current focus From the article: "A Chicago biotechnology startup with roots at the University of Illinois Chicago has raised $15 million to advance its stem cell therapy technology. From the Chicago biotech incubator Portal Innovations, Syntax Bio is developing technology based on what's known as CRISPR, short for clustered regularly interspaced short palindromic repeats, and has been historically applied in human cells as a genome-editing technology Syntax has invented a modified CRISPR system which precisely controls the timing of when certain human genes are expressed, enabling the development of methods to transform stem cells into other cells, such as killer T-cells, regulatory T-cells or beta cells - all of which can be used as cell therapies for certain diseases." Link: https://lnkd.in/gT5MwTZ7? Thank you to our investors at Astellas Pharma, Portal Innovations, LLC, Illumina Ventures, DCVC Bio, EGB Capital, Civilization Ventures, Walder Foundation for helping – we couldn’t have achieved this rollout without you And of course our amazing team: Stephen Arnovitz Caspian Harding Michaele McGregor Georgina Mancinelli, Ph.D. Renee de Pooter Jose Lopez Nick Timmins